Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | AKT1 | P31749 | 6/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587507 | 1.00 | SLC18A3 (0.50) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| Hydrochloric Acid SCHEMBL28998916 | 0.98 | SLC18A3 (0.49) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL4270092 | 0.90 | SLC18A3 (0.45) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL19337171 | 0.87 | NOTUM (0.58) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL12315997 | 0.86 | SLC18A3 (0.45) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL9917019 | 0.83 | NOTUM (0.60) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL29350111 | 0.83 | SLC18A3 (0.57) | SLC18A3SIGMAR1NOTUMHDAC1HDAC8 | |
| SCHEMBL31573145 | 0.83 | NOTUM (0.60) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL29948572 | 0.81 | SLC18A3 (0.56) | SLC18A3SIGMAR1NOTUMHDAC1HDAC8 | |
| SCHEMBL14685818 | 0.81 | SLC18A3 (0.56) | SLC18A3SIGMAR1NOTUMHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | SLC18A3 3296/4885SIGMAR1 4792/4885AKT1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.